Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture

Author(s):  Ngim Kenley, Patel Jalpa

Issue:  May/Jun 2020 - Volume 24, Number 3
View All Articles in Issue

Page(s):  242-245

Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture Page 1
Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture Page 2
Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture Page 3
Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture Page 4

Download in electronic PDF format for $75

Abstract:  Revefenacin inhalation solution, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate inhalation solution, a long-acting ß-agonist (LABA), are indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. LAMA or LABA monotherapy, or a combination of LAMA/LABA for more severe symptoms, is recommended as first-line treatment in this patient population. We conducted a study to test the physicochemical properties of revefenacin and formoterol fumarate inhalation solution admixture in support of a clinical trial evaluating the safety of these nebulized bronchodilators, administered in sequence, and as a combination, in patients with chronic obstructive pulmonary disease (NCT03573817). The admixture of these two products was evaluated for changes in appearance, pH, osmolality, active drug content, purity, and impurity/degradant levels at 25°C for up to 25 hours. No substantial changes were observed in the physicochemical properties of revefenacin inhalation solution and formoterol fumarate inhalation solution admixture, demonstrating the physicochemical compatibility and stability of the two drugs in solution for up to 25 hours at room temperature.

Related Keywords: Kenley Ngim, PhD, Jalpa Patel, MS, revefenacin, long-acting muscarinic antagonist, LAMA, formoterol fumarate, long-acting beta agonist, LABA, inhalation solutions, drug admixtures, physical stability, physical compatibility, chemical stability, chemical compatibility, chronic obstructive pulmonary disease, COPD, inhaled bronchodilators, bronchodilation, drug combinations

Related Categories: PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY, RESPIRATION/LUNG/BREATHING

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Physicochemical Stability and Compatibility of Revefenacin (LAMA) and Formoterol Fumarate (LABA) Inhalation Solution Admixture
Ngim Kenley
, Patel Jalpa
May/Jun 2020
Pg. 242-245

Physicochemical Stability of Compounded Amlodipine Besylate Suspensions in PCCA Base, SuspendIt
Graves Richard A
, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Swopes Demikka, Morris Tommy C, Pramar Yashoda V
Nov/Dec 2019
Pg. 519-527

Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline
Klemmer Anja
, Krämer Irene, Kamin Wolfgang
May/Jun 2013
Pg. 254-261

Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel
, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2007
Pg. 520-524

Long-term Stability of Vancomycin Hydrochloride in Oral Solution: The Brand Name Versus a Generic Product
Huvelle Sophie
, Godet Marie, Hecq Jean-Daniel, Gillet Patricia, Jamart Jacques, Galanti Laurence M
Jul/Aug 2016
Pg. 347-350

Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Foushee Jaime A
, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Jul/Aug 2016
Pg. 328-332

Quetiapine Fumarate 40-mg/mL Nonaqueous Oral Suspension
Allen Loyd V Jr
Jul/Aug 2011
Pg. 342

Long-term Physiochemical Stability of Concentrated Solutions of Salbutamol (Albuterol) in Polypropylene Syringes for Use in the Intensive Care Unit and in Obstetrics
Lardinois Benjamin
, Baltzis Alexandre, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin Benoît, Hecq Jean-Daniel, Galanti Laurence
Sep/Oct 2019
Pg. 434-437

Quetiapine Fumarate 10 mg/mL in Ora-Blend
Allen Loyd V Jr
Nov/Dec 2021
Pg. 506

Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride
Wu George
, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly
Jan/Feb 2018
Pg. 86-94

Long-term Physicochemical Stability of Concentrated Solutions of Noradrenaline Bitartrate in Polypropylene Syringes for Administration in the Intensive Care Unit
Lardinois Benjamin
, Pector Johan, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin B, Hecq Jean-Daniel, Galanti Laurence M
Jul/Aug 2018
Pg. 335-339

Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base SuspendIt
Pramar Yashoda V
, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Morris Tommy C, Graves Richard A
Mar/Apr 2019
Pg. 157-162

Long-term Physicochemical Stability of Concentrated Solutions of Isosorbide Dinitrate in Polypropylene Syringes for Administration in the Intensive Care Unit
Lardinois Benjamin
, Dimitriou Alexandre, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin Benoît, Hecq Jean-Daniel, Galanti Laurence M
Jan/Feb 2020
Pg. 64-68

PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing
Allen Loyd V Jr
Mar/Apr 2018
Pg. 92

Compounding an Extended Stability Admixture of Paclitaxel for Long-Term Infusion
Trissel Lawrence A
, Xu Quanyun, Martinez Juan F
Jan/Feb 1997
Pg. 49-53

The Drug Enforcement Agency's Position on "Constructive Transfer" Under the Controlled Substances Act
Pore R David
Nov/Dec 2012
Pg. 446-450

Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Trusley Craig
, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
Mar/Apr 2008
Pg. 156-160

Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C
, Ben Michel, Trusley Craig, Trissel Lawrence A
Mar/Apr 2008
Pg. 170-173

Testing the Long-Term Stability of Vancomycin Ophthalmic Solution
McLellan Christine
, Ngo Van, Pasedis Sophia, Dohlman Claes H
Sep/Oct 2008
Pg. 456-459

Compatibility and Stability of Palonosetron Hydrochloride and Propofol During Simulated Y-Site Administration
Trissel Lawrence A
, Trusley Craig, Kupiec Thomas C, Ben Michel
Jan/Feb 2009
Pg. 78-80

Return to Top